Siemens Healthineers-backed USARAD begins online CT scan consulting effort.
USARAD, a global teleradiology company backed by Siemens Healthineers, announced this week it will launch a first-of-its-kind screening program to identify patients with COVID-19.
This program, which will operate through USARAD’s SecondOpinions.com division, will connect radiologists to other providers. According to a company statement, chest CT-trained radiologists will provide screening diagnostics and consultations together with other medical specialists, including pulmonologists and infectious disease experts.
Launched in partnership with Medical Diagnostic Web (MDW), a blockchain-powered marketplace that provides access to hundreds of radiologists ready to provide diagnostic assistance, this new program allows providers to upload images through USARAD’s online service 24-hours-a-day. Radiologists will be on-hand to help either diagnose or rule out COVID-19, and as the volume of imaging studies increases, AI algorithms will be available to assist in decision-making.
Alongside its partnership with MDW, USARAD also announced a collaboration with the Israel-based Nanox Imaging to facilitate bringing Nanox’s mobile imaging system to high-risk areas, supporting preventive COVID-19 screening efforts in these locations.
“USARAD, together with its strategic partners, MDW and Nanox, is available to help patients world-wide during the current COVID-19 pandemic by leveraging the latest science and technology,” said Michael Yuz, M.D., USARAD founder and chief executive officer. “We are doing everything possible to reduce panic, bringing the peace of mind to millions of patients world-wide.”
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.